Dr. Paul Nunzio De Santis


Kite Pharma Inc: Regulatory, Commercial, and Clinical Viewpoints

Regulatory Viewpoints The market punished Kite Pharma Inc (NASDAQ:KITE)’s shares during the first half of August selling off -30% from the close on …

Gilead Sciences, Inc. (GILD): Growth Still Not Over

As we anticipated, Gilead Sciences, Inc. (NASDAQ:GILD)’s Implied VOL increased ~15-20% on a relative basis from 7/12/15 until today’s close.

Vertex Pharmaceuticals Incorporated’s Short-Term Dominance in Cystic Fibrosis is Questionable Longer Term

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)’s weekly options are pricing in a move of +/- $10 with Implied VOL currently in the 28th percentile over …

Gilead Sciences, Inc. (GILD): Owning Ahead Of Earnings To Position For Catalysts And Seasonality Outperformance

Herein we discuss several important drivers for Gilead Sciences, Inc. (NASDAQ:GILD) shares going into 2Q15/2016.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts